AMP vs REGN · P/E 12, rev $17.93B vs P/E 14, rev $14.34B
Ameriprise Financial Inc (AMP) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ameriprise Financial Inc (AMP) is a asset management company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported AMP revenue for 2024-12-31 was $17.93B. Net income was $3.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. AMP currently screens at market cap $42.43B and trailing P/E 11.8.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
AMP currently screens at market cap $42.43B and trailing P/E 11.8. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the AMP and REGN stock pages for the full models.
Not investment advice.